• Parametric curves fit to PFS (log-logistic), pre-and post-progression survival (PrePS and PPS) and TFI (both Weibull), as presented in Figures 2 to 4 , respectively, were used to predict the transitioning of patients between the model health states. These curves were based on the pre-specified alternative assessment of progression by the IRC, and were advised to be reflective of clinical practice. 2 • Baseline patient characteristics are presented in Table 1 . 
Quality of life
• Health state utility values (Table 2) , as well as utility decrements for adverse events, were derived from the LYM-3002 clinical trial, which collected EuroQoL-5 dimensions questionnaire (EQ-5D) data. Utility associated with progression from second-line treatment was retrieved from a systematic review of the literature and expert advice. 2, 3 Resource use and costs
• The proportion of patients receiving each cycle of treatment, dose reductions, transfusions, concomitant medications and subsequent treatments were all taken from LYM-3002 trial data. 4 Third-line treatment was not included as this would have added substantial additional complexity and uncertainty to the model, while it is expected to have had only a small impact on the outcomes.
• The proportion of patients experiencing adverse events was taken from LYM-3002 data. All adverse events at Grade 3 or higher reported in at least 5% of patients in either trial arm were included. Based on clinical advice, Grade 3 or higher alopecia and sepsis and Grade 2 peripheral sensory neuropathy were also included. 4 • Resource use was based on clinical advice from UK NHS clinicians (Table 3) . 2 • Costs for drugs were derived from MIMS (Monthly Index of Medical Specialties) and eMit (drugs and pharmaceutical electronic market information); for resource use and adverse events NHS reference costs were used. [5] [6] [7] Costs used for resource use are presented in Table 3 . To estimate dosing, a normal distribution of patient weight was assumed, and this distribution was used to calculate the number of vials needed per dose for intravenous drugs. This captures the level of wastage more accurately than using the mean patient weight. 8 Key: ICER, incremental cost-effectiveness ratio; IRC, independent review committee; PFS, progression-free survival; QALY, quality-adjusted life year.
Patient characteristic Baseline value
• Similar to the scenario analyses (Table 5) , one-way sensitivity analysis showed that the model is most sensitive to uncertainty in the projection of overall survival and PFS and the utility of patients who are progressed from second-line treatment. The highest incremental cost-effectiveness ratio (ICER) in one-way sensitivity analysis is only marginally above £30,000.
• The probabilistic sensitivity analysis (PSA; Figure 5 ) indicates that VR-CAP has a probability of 25% of being cost effective at a willingness-to-pay threshold of £20,000 per QALY gained. At a threshold of £30,000 per QALY gained, this probability is 76%. • VR-CAP is a cost-effective treatment for previously untreated patients with MCL who are unsuitable for HSCT in Scotland with an ICER of £23,020 per QALY gained. In September 2015, the Scottish Medicines Consortium issued positive advice for VR-CAP in this indication.
• A strength of this model is that safety, efficacy, utility and key resource use data are derived from a robust head-to-head Phase III randomised clinical trial (LYM-3002).
• The model is relatively insensitive to both parameter and structural uncertainty as tested in sensitivity analyses.
• In all clinically plausible scenarios, the ICER remains below £30,000:
• Using the Gompertz distribution was not deemed clinically plausible because of the steep drop in the tail. 2 • A time horizon of 10 years left 22.2% of patients in the R-CHOP arm and 28.5% of patients in the VR-CAP arm still alive at the end of the model, with the full benefit of improved survival therefore not captured.
• Assuming no utility benefit from remission during second-line treatment was considered overly conservative even in this aggressive disease. 2 
